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Striatal metabolism and psychomotor speed as predictors 
of motor onset in Huntington’s disease 
M. Dekker, J.C.H. van Oostrom, J.M.  Spikman, C.K.  Jurgens, M.N.W. Witjes-Ané, R.A.C. 
Roos, and K.L. Leenders.
Journal of Neurology 2014; 261: 1387-1397.
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ABSTRACT 
The clinical diagnosis of Huntington’s disease (HD) is based on the motor symptoms, 
although these can be preceded by cognitive and behavioral changes. Biomarker studies 
have shown that structural imaging modalities are useful biomarkers of HD onset, while 
functional imaging measures have been studied less often for this purpose. Our aim was 
to investigate the combined value of 18-fluorodesoxyglucose (FDG)–PET and cognitive 
measures as biomarkers of HD onset. Twenty-two premanifest mutation carriers of HD 
(PMCs) and 11 healthy controls were assessed twice with FDG–PET scan, neurological and 
neuropsychological assessments over a 2-year interval. Seventeen PMCs had an additional 
third neurological evaluation, 10 years after baseline. Disease load was defined as the 
probability of motor onset within 5 years. Metabolism in putamen, caudate and pallidum 
of PMCs was significantly lower than that of controls, at both assessments. Almost half of 
the PMCs had converted to manifest HD 10 years later and all converters had low average 
or abnormal putaminal metabolism at 2 year follow-up. In contrast, all PMCs with normal 
putaminal metabolism at 2 year follow-up remained premanifest during the following 8 
years. Furthermore, glucose metabolism of putamen explained a substantial part of the 
variance in disease load. A composite score of psychomotor tests contributed significantly 
to the prediction model as well, while cognitive performance was comparable for PMCs and 
controls. We conclude that in future clinical trials a combination of psychomotor tests and 




Huntington’s disease (HD) is an autosomal-dominant neurological disease characterized 
by progressive impairment of motor function, cognitive deterioration and psychiatric and 
behavioral symptoms. The underlying genetic defect is an expansion of a CAG trinucleotide 
repeat in the Huntingtin gene on chromosome 4, making predictive testing of at-risk 
individuals possible1. Currently, the clinical diagnosis of HD is based on the presence of 
characteristic and specific motor signs, confirmed by a positive genetic test result or a family 
history of HD. Up till now, gene mutation carriers without evident motor signs are considered 
to be in the premanifest stage of HD (pre-manifest mutation carriers: PMCs). Nevertheless, 
in PMCs cognitive impairment may be present before the onset of motor signs2, 3. Different 
HD phenotypes can already be distinguished in this premanifest stage, such as predominant 
cognitive impairment, behavioral impairment and cognitive preservation4. The age of 
onset of motor symptoms is variable and inversely related to the CAG repeat length5, 6. The 
exact moment of conversion to clinical HD cannot be predicted for an individual mutation 
carrier, but the probability of onset of motor signs within 5 years can be calculated with the 
Langbehn formula7. Although to date no cure is available, it would be helpful in identifying 
mutation carriers that are relatively close to clinical HD; thus, facilitating statistical power 
and efficacy of future disease-modifying intervention trials. Data from two large multisite 
biomarker studies have shown that cognitive, imaging, sensory, and motor measures can be 
used as quantifiable endpoints in such clinical trials8, 9. With respect to cognitive biomarkers, 
measures of emotion recognition, psychomotor speed, working memory, and executive 
function are most sensitive to early cognitive changes in PMCs, sometimes even up to a 
decade before the estimated motor onset3, 10. Structural brain imaging measures are most 
effective for detecting early changes in the brains of PMCs, revealing reduced volumes of 
striatum and white matter11. Functional imaging changes such as reduced dopamine D2 
receptor binding and alterations in brain glucose metabolism, even a specific HD related 
pattern of metabolism, may precede these structural changes in PMC brains12–15. Increases 
in regional glucose metabolism may reflect compensation for early neuronal loss or 
dysfunction; decline in these measures may herald clinical onset16. However, insufficient data 
are available about how exactly in PMCs functional imaging parameters change over time 
and whether cortical degeneration precedes or follows subtle striatal changes in HD17. Tang 
et al.18 found recently that metabolic network measurements provide a sensitive method 
to quantify disease progression in premanifest HD. The relationship between the onset of 
cognitive dysfunction and the underlying neuropathological and structural changes remains 
unclear10. A combination of functional imaging and cognitive biomarkers may provide better 
prediction of HD onset than single measures17. We combined 18-fluorodesoxyglucose 
(FDG)–PET measurements with cognitive assessments in a PMC cohort that was examined 
longitudinally. Previously, we could not detect a significant decline in striatal glucose 
metabolism or dopamine D2 receptor (raclopride) binding in these subjects over a 2-year 
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period, although both measures were lower than in controls19. Now we reanalyzed the FDG-
PET data in relation to the cognitive measures. We wanted to know which combinations of 
metabolic and cognitive measures best predict the probability of motor onset within 5 years 
for our cohort. In retrospect we were able to stratify our PMC cohort in those far from and 
those close to motor onset of HD at baseline; this could be achieved by a repeat neurological 
evaluation 10 years after the first assessments.
MATERIALS AND METHODS
Participants
The participants are part of the original cohort of 27 PMCs and 14 controls (Cs) that has 
been described in detail earlier15, 19. All subjects underwent predictive genetic testing for HD 
at the University Medical Center Groningen (UMCG) or the Leiden University Medical Center 
(LUMC) and all gave their written informed consent. Those subjects with a CAG repeat length 
of 36 or more, without HD motor signs (motor score below 5) on the Unified Huntington’s 
Disease Rating Scale (UHDRS)20 were considered PMCs. For PMCs the probability of motor 
onset within 5 years, given a person’s current age and CAG repeat length was obtained from 
the Langbehn formula7:
This ‘disease load’ at baseline was on average 0.21 with a median of 0.16; at follow-up 
this had only slightly increased towards 0.25 (Table 1). Individuals from HD families without 
the HD mutation participated as controls (Co). At baseline, all participants had a normal 
neurological examination and MRI scans were normal. Furthermore all participants had an 
mini mental status examination score higher than 2421. The educational level was scored 
now, gene mutation carriers without evident motor signs
are considered to be in the premanifest stage of HD (pre-
manifest mutation carriers: PMCs). Nevertheless, in PMCs
cognitive impairment may be present before the onset of
motor signs [2, 3]. Different HD phenotypes can already be
distinguished in this premanifest stage, such as predomi-
nant cognitive impairment, behavioral impairment and
cognitive preservation [4]. The age of onset of motor
symptoms is variable and inversely related to the CAG
repeat length [5, 6]. The exact moment of conversion to
clinical HD cannot be predicted for an individual mutation
carrier, but the probability of onset of motor signs within
5 years can be calculated with the Langbehn formula [7].
Although to date no cure is available, it would be helpful in
identifying mutation carriers that are relatively close to
clinical HD; thus, facilitating statistical power and efficacy
of future disease-modifying intervention trials.
Data from two large multisite biomarker studies have
shown that cognitive, imaging, sensory, and motor mea-
sures can be used as quantifiable endpoints in such clinical
trials [8, 9]. With respect to cognitive biomarkers, mea-
sures of emotion recognition, psychomotor speed, working
memory, and executive function are most sensitive to early
cognitive changes in PMCs, sometimes even up to a decade
before the estimated motor onset [3, 10]. Structural brain
imaging measures are most effective for detecting early
changes in the brains of PMCs, revealing reduced volumes
of striatum and white matter [11]. Functional imaging
changes such as reduced dopamine D2 receptor binding
and alterations in brain glucose metabolism, even a specific
HD related pattern of metabolism, may precede these
structural changes in PMC brains [12–15]. Increases in
regional glucose metabolism may reflect compensation for
early neuronal loss or dysfunction; decline in these mea-
sures may herald clinical onset [16]. However, insufficient
data are available about how exactly in PMCs functional
imaging parameters change over time and whether cortical
degeneration precedes or follows subtle striatal changes in
HD [17]. Tang et al. [18] found recently that metabolic
network measurements provide a sensitive method to
quantify disease progression in premanifest HD. The rela-
tionship between the onset of cognitive dysfunction and the
underlying neuropathological and structural changes
remains unclear [10].
A combination of functional imaging and cognitive
biomarkers may provide better prediction of HD onset than
single measures [17]. We combined 18-fluorodesoxyglu-
cose (FDG)–PET measurements with cognitive assess-
ments in a PMC cohort that was examined longitudinally.
Previously, we could not detect a significant decline in
striatal glucose metabolism or dopamine D2 receptor (ra-
clopride) binding in these subjects over a 2-year period,
although both measures were lower than in controls [19].
Now we re-analyzed the FDG-PET data in relation to the
cognitive measures. We wanted to know which combina-
tions of metabolic and cognitive measures best predict the
probability of motor onset within 5 years for our cohort. In
retrospect we were able to stratify our PMC cohort in those
far from and those close to motor onset of HD at baseline;
this could be achieved by a repeat neurological evaluation
10 years after the first assessments.
Materials and methods
Participants
The participants are part of the original cohort of 27 PMCs
and 14 controls (Cs) that has been described in detail
earlier [15, 19]. All subjects underwent predictive genetic
t sting for HD at the University Medical Center Groningen
(UMCG) or the Leiden University Medical Center
(LUMC) and all gave their written informed consent.
Those subjects with a CAG repeat length of 36 or more,
without HD motor signs (motor score below 5) on the
Unified Huntington’s Disease Rating Scale (UHDRS) [20]
were considered PMCs. For PMCs the probability of motor
onset within 5 years, given a person’s current age and CAG
repeat length was obtained from the Langbehn formula [7]:
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3
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This ‘disease load’ at baseline was on average 0.21 with
a median of 0.16; at follow-up this had only slightly
increased towards 0.25 (Table 1). Individuals from HD
families without the HD mutation participated as controls
(C ). At baseline, all participants had a normal neurolog-
cal examination and MRI scan were normal. Furthermor
all participants had an mini mental status examination
score higher than 24 [21]. The educational level was scored
with a Dutch classification scale [22].
Of the original group of 41, 33 participants (22 PMCs
and 11 Co) were seen after 2 years (see Fig. 1). The reason
for drop out was self-withdrawal (n = 4) or technical
failures in obtaining repeat PET-scans (n = 4). We ana-
lyzed the baseline (T0) and follow-up (T1) results from the
FDG–PET scan and neuropsychological assessment
(NPA). Data were complete for nearly all participants,
except for 2 PMCs who had missing data for NPA at T0
and two Co by whom FDG–PET scans could not be carried
out successfully.
5 of the 22 PMCs did not have a neurological exami-
nation 10 years after baseline; 3 persons could not be




participation. 8 of the remaining 17 PMCs (47 %) had
converted to the clinical (motor) stage of HD (UHDRS
motor score: M = 11.9; SD = 4.2) after 10 years. The
other 9 PMCs did not have significant motor symptoms
(UHDRS motor score: M = 4.8; SD = 3.5) at that time.
Those PMCs that had converted to HD during the 10 years
are hereafter designated as PMCs close to motor onset of
HD (PMC ‘close’), the other 9 PMCs are designated as
PMCs far from motor onset of HD (PMC ‘far’). The PMCs
and Co were comparable with respect to age, educational
level and gender (Table 1). The two PMC subgroups
(‘close’ and ‘far’) had comparable demographic charac-
teristics as well (Table 1). The disease load for PMCs
‘close’ was higher than for PMCs ‘far’, but this did not
reach significance. UHDRS total functional capacity at
baseline was comparable for both PMC subgroups (scores
12 or 13).
Procedure
Neurological assessment and assessments of FDG–PET
scans were done by a single blinded movement disorder
neurologist at the UMCG (JvO). The NPA took place in a
fixed order and was carried out by trained neuropsychol-
ogists, either at the UMCG (MHD) or the LUMC (MNW,
CKJ). All subjects were tested and scanned twice, with a
mean interval of about 2.5 years. For most subjects the
NPA was performed prior to the FDG–PET scan on 1 or 2
subsequent days, with a maximum interval of 3 months. At
baseline this could unfortunately not be realised for a
subgroup of our participants (median interval = 9 months,
range 0–21 months). Neurological assessment 10 years




NPA took place based on the CAPIT-HD protocol [23]. In
the current study we analyzed the results of only those tests
known to be sensitive to early cognitive change in pre-
manifest HD: the stroop colour word test [24], the trail
making test (TMT) [25] and the symbol digit modalities
test (SDMT) [26]. In addition we analyzed scores on letter
fluency (FAS) [27] and some subtests of the Wechsler
memory scale (WMS); logical memory (total immediate
recall), digit span (forward and backward) and associate
learning [28].
Test scores were analysed separately, but were also
combined to represent three cognitive domains: psychomo-
tor speed (PmS), memory (M) and executive function (EF).
Stroop and SDMT scores, both representing the number of
Table 1 Demographic ch racteristics of participants at baseline
Characteristics All PMCs (n = 22) PMCs ‘far’ (n = 9) PMCs ‘close’ (n = 8) Controls (n = 11)
Gender: women n (%) 14 (64) 6 (67) 4 (50) 4 (55)
Age at NPA (years) 38.7 ± 6.7 (31–56) 39.4 ± 7.2 (31–56) 40.6 ± 7.0 (32–49) 42.5 ± 8.9 (26–54)
Educational levela 5.1 ± 1.0 (3–7) 4.7 ± 0.7 (4–6) 5.4 ± 1.3 (3–7) 5.1 ± 1.0 (3–6)
CAG repeat length 42.6 ± 2.3 (39–47) 41.9 ± 2.6 (39–47) 42.4 ± 1.8 (40–45) na
Disease loadb 0.21 ± 0.18 (0.01–0.65) 0.17 ± 0.19 (0.01–0.65) 0.21 ± 0.12 (0.08–0.39) na
Va ues are mean ± standard deviation (range) or frequency (percentage)
na not applicable, NPA neuropsychological assessment, PMCs ‘far’/‘close’ preclinical mutation carriers far from/close to motor onset, based on
the UHDRS DCL score at 10 years after baseline
a Verhage classification
b Probability of motor onset within 5 years
Fig. 1 Flow chart of participants and drop out during follow up. T0
baseline, T1 follow up two-and-a-half years after baseline, T2 follow
up 10 years after baseline, PMCs premanifest mutation carriers of
Huntington’s disease, Co controls NA neurological assessment, PET
positron emission tomography, NPA neuro psychological assessment
J Neurol
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with a Dutch classification scale22.
Of the original group of 41, 33 participants (22 PMCs and 11 Co) were seen after 2 years (see 
Fig. 1). The reason for drop out was self-withdrawal (n = 4) or technical failures in obtaining 
repeat PET-scans (n = 4). We analyzed the baseline (T0) and follow-up (T1) results from the 
FDG–PET scan and neuropsychological assessment (NPA). Data were complete for nearly all 
participants, except for 2 PMCs who had missing data for NPA at T0 and two Co by whom 
FDG–PET scans could not be carried out successfully.
5 of the 22 PMCs did not have a neurological examination 10 years after baseline; 3 
persons could not be contacted anymore and 2 PMCs declined further participation. 8 of 
the remaining 17 PMCs  (47 %) had converted to the clinical (motor) stage of HD (UHDRS 
motor score: M = 11.9; SD = 4.2) after 10 years. The other 9 PMCs did not have significant 
motor symptoms (UHDRS motor score: M = 4.8; SD = 3.5) at that time. Those PMCs that had 
converted to HD during the 10 years are hereafter designated as PMCs close to motor onset 
of HD (PMC ‘close’), the other 9 PMCs are designated as PMCs far from motor onset of HD 
(PMC ‘far’). The PMCs and Co were comparable with respect to age, educational level and 
gender (Table 1). The two PMC subgroups (‘close’ and ‘far’) had comparable demographic 
characteristics as well (Table 1). The disease load for PMCs ‘close’ was higher than for PMCs 
‘far’, but this did not reach significance. UHDRS total functional capacity atbaseline was 
comparable for both PMC subgroups (scores 12 or 13).
Procedure
Neurological assessment and assessments of FDG–PET scans were done by a single blinded 
movement disorder neurologist at the UMCG (JvO). The NPA took place in a fixed order and 
Fig. 1 Flow chart of participants and drop out during follow up. T0 baseline, T1 follow up two-and-a-half years 
after baseline, T2 follow up 10 years after baseline, PMCs premanifest mutation carriers of Huntington’s disease, 
Co controls NA neurological assessment, PET positron emission tomography, NPA neuro psychological assessment
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was carried out by trained neuropsychologists, either at the UMCG (MHD) or the LUMC 
(MNW, CKJ). All subjects were tested and scanned twice, with a mean interval of about 
2.5 years. For most subjects the NPA was performed prior to the FDG–PET scan on 1 or 2 
subsequent days, with a maximum interval of 3 months. At baseline this could unfortunately 
not be realised for a subgroup of our participants (median interval = 9 months, range 0–21 




NPA took place based on the CAPIT-HD protocol23. In the current study we analyzed the 
results of only those tests known to be sensitive to early cognitive change in premanifest HD: 
the stroop colour word test24, the trail making test (TMT)25 and the symbol digit modalities 
test (SDMT)26. In addition we analyzed scores on letter fluency (FAS) 27 and some  subtests 
of the Wechsler memory scale (WMS); logical memory (total immediate recall), digit span 
(forward and backward) and associate learning28.
Test scores were analysed separately, but were also combined to represent three cognitive 
domains: psychomotor speed (PmS), memory (M) and executive function (EF). correct 
answers,  were transformed to time  scores (time needed to complete the whole test). 
Subsequently, all test scores were converted to z-scores based on the means and standard 
deviations of the control data. The PmS score was calculated as  the non-weighted average 
z-score of time scores on the stroop colour naming, stroop word reading, SDMT and TMT 
part A. The same was done for the M score based on the WMS subtasks logical memory 
immediate recall, associate learning, and digit span forward, representing working memory 
and episodic memory. The EF score contains the non-weighted average z-score for the 
stroop interference index (interference card/colour card), the TMT index (part B/part A), the 
digit span backwards total correct span and the letter fluency (using the letters F-A-S; total 
correct answers). This combined EF score represents aspects of inhibitory control, cognitive 
flexibility, generating and manipulating information from memory.
Imaging measures
Static 18-fluorodesoxyglucose (FDG)-PET scans were performed and analyzed according 
to previously published protocols15, 19, aiming to minimize variability due to operator and 
analysis factors. We expressed FDG–PET data as a normalized regional glucose metabolic 
index (GMI), indicating regional activity relative to average brain metabolism. The results 
are presented as means of left and right GMI. We analyzed GMI in the caudate nucleus, 
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putamen, pallidum, and dorsolateral prefrontal cortex (DLPFC). The latter was composed as 
an average score of the Montreal Neurological Institute (MNI) coordinates for superior and 
middle frontal gyrus.
Statistical analyses
Given the great individual variability in onset and presentation of first cognitive symptoms, 
we also calculated individual classification scores for PmS, M, and EF as well as GMI in 
each selected brain region. These classification scores were considered ‘abnormal’ for an 
individual when below two standard deviations (SD) of the control mean (M), ‘low average’ 
when between one and two SD below M and ‘normal’ above one SD below the control 
mean.
Data were analyzed with IBM SPSS statistics 20 for Windows. Nonparametric tests were 
used since the data were not normally distributed and the sample size is rather small. 
Group comparisons were made with Chi-squared tests and Mann–Whitney tests when 
appropriate. General linear model repeated measures Ancova analyses were carried out 
to analyze possible group, time, and interaction effects for the cognitive and imaging data. 
The age was included as a covariate to control for possible age-related differences within 
and between groups. For correlations between the measures, partial correlations were 
computed, controlling for the influence of age as well. Spearman’s Rho was computed when 
appropriate. Linear regression analyses were carried out to analyze the contribution of 
these variables to the prediction of disease load. We took one-sided alpha levels, since we 
expected the PMC group to perform worse on all measures as compared to Co. For post hoc 
multiple comparisons, the Bonferroni–Holm correction was applied29.
RESULTS
Group comparisons
PMCs showed a significantly lower glucose metabolism than Co in putamenF(1, 28) = 17.3, 
p = 0.0001, caudate nucleusF(1, 28) = 5.5, p = 0.01 and pallidumF(1,28) = 5.3, p = 0.01 at 
T0 as well as at T1 (Table 2). Frontal metabolism was comparable for both groups  at both 
assessments. Furthermore, group analyses for the cognitive measures did not reveal any 
significant differences between PMCs and Co at both assessments. Additional comparisons 
between PMCs ‘far’ and PMCs ‘close’ did not show any significant differences as well, 
neither on imaging, nor on cognition measures. All scores remained stable during the 2 year 
follow-up period, for PMCs as well as Co (Table 2).
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Individual performances
The frequencies of individual classifications of glucose metabolism and cognitive 
performance (normal, low average, abnormal) of both PMCs and Co are shown in Table 3. 
PMCs had significantly more abnormal putaminal GMI scores than Co at T0 (p = 0.0006) as 
well as at T1 (p = 0.0002). Fourteen PMCs (63.6 %) had an abnormal putaminal  classification 
score  at  T0,  while  3  PMCs (13.6 %) had a low average score and 5 PMCs (22.8 %) had a 
normal score. At T1, 11 PMCs (50 %) had an abnormal score for putaminal metabolism, while 
5 PMCs (22.7 %) had a low average score and 6 PMCs (27.3 %) had a normal score. Further 
inspection of the data shows that 11 of the original 14 PMCs with abnormal putaminal 
score, 15 % had a low normal PmS score and 65 % had a
normal PmS score, while all Co had normal scores. At T1
the distributions of PmS scores were comparable for PMCs
and Co. Classification scores for executive function (EF)
and memory (M) were comparable as well, at both
assessments.
In retrospect, when comparing on these classification
scores PMCs ‘far’ and PMCs ‘close’, we only found a bor-
derline significant difference for putaminal GMI (p = 0.04)
at T1. More specifically, all PMCs ‘close’ then had an
abnormal or low average putaminal score and none of them
had a normal putaminal score, while 45 % of PMCs ‘far’ still
had a normal putaminal GMI score. In other words, none of
the PMCs with still a normal putaminal score at T1, had
developed motor symptoms of HD 10 years after baseline
(T2). PMCs ‘far’ and PM s ‘close’ had comparable distri-
butions on the other imaging and cognition classification
scores at both measurements (see Table 3).
Table 2 Results of two way repeated measures Ancova (corrected for age) for PMCs and Co
Measure PMCs at T0 PMCs at T1 Controls at T0 Controls at T1 Time Group Time 9 group
Cognition: tests n = 20 n = 22 n = 11 n = 11 p p p
SDMTa 57.45 (10.84) 55.14 (9.38) 55.45 (8.80) 50.82 (7.86) 0.04 ns ns
Stroopb
Colour 76.68 (9.29) 74.67 (9.64) 79.82 (13.05) 81.91 (11.42) 0.02 ns 0.02
Word 98.42 (13.60) 99.59 (13.96) 109.18 (15.18) 108.00 (15.19) ns 0.02 ns
Interference 45.95 (7.00) 45.09 (5.90) 45.18 (8.78) 46.09 (9.39) ns ns ns
I/c indexc 1.67 (0.24) 1.68 (0.20) 1.79 (0.21) 1.81 (0.24) ns 0.01 ns
TMTd
Part A 30.70 (12.80) 29.77 (12.65) 23.82 (4.79) 28.36 (6.15) ns ns ns
Part B 67.55 (29.02) 53.82 (23.70) 61.64 (19.48) 53.45 (16.34) 0.01 ns ns
B/A indexe 2.30 (0.65) 1.93 (0.94) 2.61 (0.64) 1.89 (0.46) 0.04 ns ns
WMS
Log. mem.f 9.80 (2.94) 9.31 (3.86) 9.11 (3.91) 9.93 (3.44) ns ns ns
Assoc. learng 18.13 (2.70) 17.86 (2.50) 18.55 (1.60) 17.52 (3.30) ns ns ns
DS fw 6.00 (1.08) 5.86 (1.25) 5.64 (1.03) 6.18 (1.08) 0.03 ns 0.04
DS bw 4.60 (1.50) 4.73 (1.20) 4.82 (1.33) 4.91 (1.30) ns ns ns
Letter fluency FAS 38.00 (9.40) 36.09 (10.50) 35.00 (8.12) 34.09 (10.11) ns ns ns
Combined scores
PmS score 0.63 (1.18) 0.26 (1.05) -0.00 (0.71) 0.00 (0.77) ns ns ns
M score 0.09 (0.78) -0.12 (0.77) -0.00 (0.65) 0.00 (0.77) ns ns ns
EFscore -0.29 (0.73) -0.19 (0.89) -0.01 (0.62) -0.00 (0.59) ns ns ns
Imaging: GMI n = 22 n = 22 n = 9 n = 9
Caudate 0.80 (0.11) 0.77 (0.11) 0.88 (0.09) 0.85 (0.08) ns 0.01* ns
Putamen 1.10 (0.06) 1.08 (0.07) 1.20 (0.05) 1.18 (0.04) ns 0.0001* ns
Pallidum 0.99 (0.05) 0.99 (0.05) 1.05 (0.06) 1.03 (0.06) ns 0.01* 0.03
DLPFC 1.09 (0.03) 1.07 (0.04) 1.07 (0.03) 1.07 (0.02) ns ns ns
Values are mean (standard deviation)
SDMT symbol digit modalities test, TMT trail making test in seconds, WMS wechsler memory scale, DS fw digit span forward maximum span
correct, DS bw digit span backward maximum span correct, PmS score psychomotor speed average z-score,M score memory average z-score, EF
score executive function average z-score, GMI glucose metabolic index, DLPFC dorsolateral prefrontal cortex, T0 baseline, T1 follow up, ns not
significant
* Bold value indicates significant p value\Bonferroni–Holm corrected a (one-sided)
a Number correct in 90 s
b Number correct in 45 s
c Interference card in seconds/colour card in seconds
d In seconds
e TMT part B/part A
f Subtest logical memory, average correct of stories 1 and 2






metabolism at baseline still had an abnormal score at follow-up. The other 3 PMCs with an 
abnormal putaminal score at baseline now had a low average putaminal score at T1. The 
caudate, DLPFC and pallidum showed comparable distributions of these scores for PMCs 
and Cs at both assessments.
To find out whether the classification scores of PMCs
glucose metabolism and cognitive performance were cor-
related to each other, Spearman correlations were
computed (the results are shown in Table 4). After Bon-
ferroni–Holm correction, we did not find any significant
correlations between the individuals imaging and cognitive























n = 20 n = 9 n = 8 n = 22 n = 9 n = 8 n = 11 n = 11
PmS
Normala 13 (65.0) 5 (71.4) 5 (62.5) 18 (81.8) 8 (88.9) 7 (87.5) 11 (100) 10 (90.9) 0.015*, d
Low averageb 3 (15.0) 1 (14.3) 1 (12.5) 2 (9.1) 0 1 (12.5) 0 1 (9.1) nse
Abnormalc 4 (20.0) 1 (14.3) 2 (25.0) 2 (9.1) 1 (11.1) 0 0 0
Missing 2 2 0 0 0 0 0 0
Memory
Normal 18 (90.0) 6 (85.7) 8 (100) 19 (86.4) 7 (77.8) 8 (100) 11 (100) 11 (100) ns
Low average 2 (10.0) 1 (14.3) 0 3 (13.6) 2 (22.2) 0 0 0 ns
Abnormal 0 0 0 0 0 0 0 0
Missing 2 2 0 0 0 0 0 0
EF
Normal 18 (90.0) 7 (100) 7 (87.5) 20 (91.0) 8 (88.9) 7 (87.5) 11 (100) 11 (100) ns
Low average 2 (10.0) 0 1 (12.5) 1 (4.5) 0 1 (12.5) 0 0 ns
Abnormal 0 0 0 1 (4.5) 1 (11.1) 0 0 0
Missing 2 2 0 0 0 0 0 0
Imaging scores n = 22 n = 9 n = 8 n = 22 n = 9 n = 8 n = 11 n = 11
DLPFC
Normal 19 (86.4) 7 (77.8) 7 (87.5) 16 (72.8) 5 (55.6) 7 (87.5) 8 (88.9) 7 (77.8) ns
Low average 3 (13.6) 2 (22.2) 1 (12.5) 3 (13.6) 3 (33.3) 0 1 (11.1) 2 (22.2) ns
Abnormal 0 0 0 3 (13.6) 1 (11.1) 1 (12.5) 0 0
Caudate
Normal 13 (59.1) 7 (77.8) 3 (37.5) 12 (54.5) 6 (66.7) 3 (37.5) 7 (77.8) 8 (88.9) ns
Low average 5 (22.7) 0 3 (37.5) 4 (28.2) 1 (11.1) 3 (37.5) 2 (22.2) 1 (11.1) 0.03 ns
Abnormal 4 (18.2) 2 (22.2) 2 (25.0) 6 (27.3) 2 (22.2) 2 (25) 0 0
Putamen
Normal 5 (22.8) 2 (22.2) 1 (12.5) 6 (27.3) 4 (44.5) 0 7 (77.8) 7 (77.8) 0.0006*
Low average 3 (13.6) 2 (22.2) 1 (12.5) 5 (22.7) 2 (22.2) 3 (37.5) 2 (22.2) 2 (22.2) 0.0002*
Abnormal 14 (63.6) 5 (55.6) 6 (75.0) 11 (50.0) 3 (33.3) 5 (72.5) 0 0
Pallidum
Normal 9 (40.9) 4 (44.5) 2 (25.0) 15 (68.2) 6 (66.7) 6 (75.0) 7 (77.8) 8 (88.9) 0.03 ns
Low average 11 (49.1) 3 (33.3) 6 (75.0) 5 (22.7) 2 (22.2) 1 (12.5) 2 (22.2) 1 (11.1) ns
Abnormal 2 (10.0) 2 (22.2) 0 2 (9.1) 1 (11.1) 1 (12.5) 0 0
Values are frequencies (valid percentage) and results of Mann–Whitney tests
T0 baseline, T1 follow up, PmS psychomotor speed average z-score, M memory average z-score, EF executive function average z-score, DLPFC
dorsolateral prefrontal cortex, ns not significant
* Bold value indicates significant p value\Bonferroni–Holm corrected a (one-sided)
a Score above one standard deviation (SD) below the controls mean (M)
b Score between one and two SD below M
c Score below two SD of M
d p value for group difference between all PMCs and Co at T0





As to cognitive performance, PMCs had significantly worse baseline scores on psychomotor 
speed (PmS) than Co (p = 0.015):  20 % of  PMCs had  an  abnormal PmS score, 15 % had a 
low normal PmS score and 65 % had a normal PmS score, while all Co had normal scores. At 
T1 the distributions of PmS scores were comparable for PMCs and Co. Classification scores 
for executive function (EF) and memory (M) were comparable as well, at both assessments.
In retrospect, when comparing on these classification scores PMCs ‘far’ and PMCs ‘close’, 
we only found a borderline significant difference for putaminal GMI (p = 0.04) at T1. More 
specifically, all PMCs ‘close’ then had an abnormal or low average putaminal score and none 
of them had a normal putaminal score, while 45 % of PMCs ‘far’ still had a normal putaminal 
GMI score. In other words, none of the PMCs with still a normal putaminal score at T1, had 
developed motor symptoms of HD 10 years after baseline (T2). PMCs ‘far’ and PMCs ‘close’ 
had comparable distributions on the other imaging and cognition classification scores at 
both measurements (see Table 3). To find out whether the classification scores of PMCs 
glucose metabolism and cognitive performance were correlated   to   each   other,   Spearman 
correlations were computed (the results are shown in Table 4). After Bonferroni–Holm 
correction, we did not find any significant correlations between the individuals imaging and 
cognitive classification scores, but at T0 a trend was seen for a positive correlation between 
glucose metabolism in caudate and PmS performance (p = 0.02). At T1 a comparable trend 
was found (p = 0.03) and additional even stronger trends were seen for positive correlations 
of PmS with pallidum and putamen metabolism (p = 0.01    and p = 0.02, respectively).
classification scores, but at T0 a trend was seen for a
positive correlation between glucose metabolism in cau-
date and PmS performance (p = 0.02). At T1 a comparable
trend was found (p = 0.03) and additional even stronger
trends were seen for positive correlations of PmS with
pallidum and putamen metabolism (p = 0.01 and
p = 0.02, respectively).
Correlations between disease load and other measures
Table 5 shows that the conditional probability of onset of
motor symptoms within 5 years (disease load) from T0 was
most strongly and negatively correlated with putaminal
metabolism (p B 0.001) and the PmS score (p B 0.001),
after correction for age. All the separate test scores that PmS
consists of, as well as the WMS logical memory score, were
also significantly correlated with disease load (p values
between 0.003 and 0.01). In addition striatal and pallidal
metabolism showed significant negative correlations with
disease load (p = 0.004 and p = 0.005, respectively).
At T1, comparable and in part even stronger results were
found (Table 5). In addition disease load was now signif-
icantly correlated with the colour word card of the stroop
test (p = 0.01) and the TMT part B (p = 0.03).
Prediction model
The measures with the highest, significant, correlations
with disease load at T0 (see Table 5) were included, one by
one, in a linear regression analysis. Age did not contribute
significantly to the model and was therefore left out of the
analyses. The largest adjusted R2 for the contributions of
the separate measures to disease load were found for the
PmS score (45 %) and putaminal GMI (44 %); F(1,
19) = 16.32, p B 0.001 and F(1, 21) = 17.73, p B 0.001,
respectively (see Table 6). Most psychomotor (sub-) tests
contributed significantly to the variance in disease load.
The SDMT explained 35 % of total variance, TMT part A
26 %, stroop colour naming card 25 % and the stroop word
reading card explained 23 % of total variance (corrected
p values between 0.002 and 0.01). The WMS subtest log-
ical memory explained 22 % of the variance in disease load
(p = 0.01). Of the imaging measures the pallidal GMI
accounted for 24 % of the variance (p = 0.007) but the
caudate GMI did not contribute significantly to disease
load.
Table 4 Correlations between the individual classification scores of















Putamen 0.27 0.44 0.26 0.07 -0.12 -0.08
Caudate 0.46 0.42 0.02 0.26 0.02 -0.07
Pallidum 0.32 0.47 0.26 0.24 -0.36 -0.21
DLPFC -0.17 -0.04 -0.08 0.09 -0.08 -0.19
Values are Spearman’s Rho correlations
Bold value indicates close to significant p value\Bonferroni–Holm
corrected alpha (one-sided)
T0 baseline, T1 follow up, PmS psychomotor speed average z-score,
M memory average z-score, EF executive function average z-score,
DLPFC dorsolateral prefrontal cortex
Table 5 Correlations between disease load and cognitive and
imaging measures for PMCs at T0 (n = 20) and T1 (n = 22)
Measures Disease load T0 Disease load T1
Cognitive measures
PmS score 20.69* 20.83*
SDMTa 20.62* 20.75*
TMTb part A 0.54* 0.68*
Stroopc colour 20.55* 20.53*
Stroop word 20.53* 20.52*
Stroop interference -0.18 20.48*
TMT part B 0.32 0.41*
EF score -0.13 0.10
TMT B/A indexd -0.32 -0.13
Stroop i/c indexe -0.24 0.03
Letter fluency FAS -0.14 -0.35
DS bw -0.08 -0.25
M score -0.24 -0.39
WMS logical memf 20.51* 20.56*
WMS assoc learng -0.19 -0.37
DS fw 0.15 0.03
Imaging measures
GMI putamen 20.69* 20.70*
GMI striatum 20.56* 20.56*
GMI pallidum 20.55* 20.55*
GMI caudate -0.36 -0.35
GMI DLPFC -0.20 -0.21
Values are partial correlations, corrected for the influence of age
SDMT symbol digit modalities test, TMT trail making test in seconds,
WMS wechsler memory scale, DS fw digit span forward maximum
span correct, DS bw digit span backward maximum span correct, PmS
score psychomotor speed average z-score, M score memory average
z-score, EF score executive function average z-score, GMI glucose
metabolic index, DLPFC dorsolateral prefrontal cortex, T0 baseline,
T1 follow up
* Bold value indicates significant p value\Bonferroni–Holm cor-
rected a (one-sided)
a Number correct in 90 s
b In seconds
c Number correct in 45 s
d TMT part B/part A
e Interference card in seconds/colour card in seconds
f Subtest logical memory, average correct of stories 1 and 2




Correlations between disease load and other measures
Table 5 shows that the conditional probability of onset of motor symptoms within 5 
years (disease load) from T0 was most strongly and negatively co related with putaminal 
metabolism (p ≤ 0.001) and the PmS score (p ≤ 0.001), after correction for age. All the 
separate test scores that PmS consists of, as well as the WMS logical memory score, were 
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classification scores, but at T0 a trend was seen for a
positive correlation between glucose metabolism in cau-
date and PmS performance (p = 0.02). At T1 a comparable
trend was found (p = 0.03) and additional even stronger
trends were seen for positive correlations of PmS with
pallidum and putamen metabolism (p = 0.01 and
p = 0.02, respectively).
Correlations between disease load and other measures
Table 5 shows that the conditional probability of onset of
motor symptoms within 5 years (disease load) from T0 was
most strongly and negatively correlated with putaminal
metabolism (p B 0.001) and the PmS score (p B 0.001),
after correction for age. All the separate test scores that PmS
consists of, as well as the WMS logical memory score, were
also significantly correlated with disease load (p values
between 0.003 and 0.01). In addition striatal and pallidal
metabolism showed significant negative correlations with
disease load (p = 0.004 and p = 0.005, respectively).
At T1, comparable and in part even stronger results were
found (Table 5). In addition disease load was now signif-
icantly correlated with the colour word card of the stroop
test (p = 0.01) and the TMT part B (p = 0.03).
Prediction model
The measures with the highest, significant, correlations
with disease load at T0 (see Table 5) were included, one by
one, in a linear regression analysis. Age did not contribute
significantly to the model and was therefore left out of the
analyses. The largest adjusted R2 for the contributions of
the separate measures to disease load were found for the
PmS score (45 %) and putaminal GMI (44 %); F(1,
19) = 16.32, p B 0.001 and F(1, 21) = 17.73, p B 0.001,
respectively (see Table 6). Most psychomotor (sub-) tests
contributed significantly to the variance in disease load.
The SDMT explained 35 % of total variance, TMT part A
26 %, stroop colour naming card 25 % and the stroop word
reading card explained 23 % of total variance (corrected
p values between 0.002 and 0.01). The WMS subtest log-
ical memory explained 22 % of the variance in disease load
(p = 0.01). Of the imaging measures the pallidal GMI
accounted for 24 % of the variance (p = 0.007) but the
caudate GMI did not contribute significantly to disease
load.
Table 4 Correlations between the individual classification scores of















Putamen 0.27 0.44 0.26 0.07 -0.12 -0.08
Caudate 0.46 0.42 0.02 0.26 0.02 -0.07
Pallidum 0.32 0.47 0.26 0.24 -0.36 -0.21
DLPFC -0.17 -0.04 -0.08 0.09 -0.08 -0.19
Values are Spearman’s Rho correlations
Bold value indicates close to significant p value\Bonferroni–Holm
corrected alpha (one-sided)
T0 baseline, T1 follow up, PmS psychomotor speed average z-score,
M memory average z-score, EF executive function average z-score,
DLPFC dorsolateral prefrontal cortex
Table 5 Correlations between disease load and cognitive and
imaging measures for PMCs at T0 (n = 20) and T1 (n = 22)
Measures Disease load T0 Disease load T1
Cognitive measures
PmS score 20.69* 20.83*
SDMTa 20.62* 20.75*
TMTb part A 0.54* 0.68*
Stroopc colour 20.55* 20.53*
Stroop word 20.53* 20.52*
Stroop interference -0.18 20.48*
TMT part B 0.32 0.41*
EF score -0.13 0.10
TMT B/A indexd -0.32 -0.13
Stroop i/c indexe -0.24 0.03
Letter fluency FAS -0.14 -0.35
DS bw -0.08 -0.25
M score -0.24 -0.39
WMS logical memf 20.51* 20.56*
WMS assoc learng -0.19 -0.37
DS fw 0.15 0.03
Imaging measures
GMI putamen 20.69* 20.70*
GMI striatum 20.56* 20.56*
GMI pallidum 20.55* 20.55*
GMI caudate -0.36 -0.35
GMI DLPFC -0.20 -0.21
Values are partial correlations, corrected for the influence of age
SDMT symbol digit modalities test, TMT trail making test in seconds,
WMS wechsler memory scale, DS fw digit span forward maximum
span correct, DS bw digit span backward maximum span correct, PmS
score psychomotor speed average z-score, M score memory average
z-score, EF score executive function average z-score, GMI glucose
metabolic index, DLPFC dorsolateral prefrontal cortex, T0 baseline,
T1 follow up
* Bold value indicates significant p value\Bonferroni–Holm cor-
rected a (one-sided)
a Number correct in 90 s
b In seconds
c Number correct in 45 s
d TMT part B/part A
e Interference card in seconds/colour card in seconds
f Subtest logical memory, average correct of stories 1 and 2





Given the small sample size the final prediction model
was restricted to a maximum of three predictors that were
entered together, in a multiple linear regression model. The
best model for predicting disease load at baseline consisted
of the putaminal GMI and the PmS score, together
explaining 67 % of the total variance in disease load; F(2,
19) = 20.06, p\ 0.001, described in the following
regression formula: disease load = 1.94–1.61 9 GMI
Putamen ? 0.078 9 PmS.
The same regression analyses were carried out for the
T1 data and resulted in comparable, even stronger findings.
Putaminal GMI and PmS together explained 68 % of total
variance in disease load [F(2, 21) = 22.87, p\ 0.001],
now yielding the following equation: disease
load = 1.19–0.89 9 GMI Putamen ? 0.11 9 PmS.
Discussion
We studied a well-defined group of premanifest mutation
carriers of HD with imaging and cognitive assessment at
two time points, 2 years apart, in order to identify the best
combination of clinical markers to predict the probability
of HD motor onset. This motor onset could be determined
accurately as patients were re-assessed 10 years after the
initial examination. The combination of glucose metabo-
lism in putamen and a composite score for psychomotor
speed accounts for two-thirds of variance in the calculated
probability of motor onset within 5 years. This model holds
true—and thus should be considered validated—for mea-
surements obtained at 2-year-follow-up. The relevance of
combined clinical measures in predicting disease onset and
disease progression had been established before [8, 9, 30],
as well has the value of FDG–PET to detect early func-
tional brain changes in PMCs [14]. Our study is the first to
show that the combination of FDG–PET and cognitive
(psychomotor speed) measures has significant predictive
value.
Our functional imaging data replicate earlier findings on
metabolic alterations in premanifest HD. We showed that
putaminal metabolism was abnormal in almost two-thirds
of PMCs at baseline and in half of PMCs at 2-year-follow-
up. This slight paradoxical decrease in the number of
abnormal putaminal metabolism scores may be explained
by the phenomenon of ‘regression towards the mean’. We
made a rather artificial classification for individual imaging
and cognitive performances on the basis of z-scores. Three
PMCs with an abnormal putaminal score at baseline (z-
scores slightly below-2), ‘improved’ to the low average
level at follow-up (with z-scores slightly above-2), while
their absolute putaminal scores did not change that much.
Furthermore, the average putaminal metabolism of the
PMC group remained stable during follow-up. We also
found abnormal caudate and pallidal metabolism in smaller
subgroups of our cohort; however, these were not signifi-
cantly different from Co. In line with the previous
Table 6 Results from the linear regression analyses for the predic-







PmS score 0.45 <0.001* 0.63 <0.001*
SDMTa 0.35 0.002* 0.54 <0.001*
TMTb part A 0.26 0.007* 0.42 <0.001*
Stroopc colour 0.25 0.008* 0.23 0.008*
Stroop word 0.23 0.01* 0.21 0.01*
WMS log memd 0.22 0.01* 0.27 0.004*
TMT part B 0.05 0.09 0.12 0.03*
Stroop interference -0.02 0.22 0.19 0.01*
Imaging measures
GMI Putamen 0.44 <0.001* 0.46 <0.001*
GMI Striatum 0.23 0.007* 0.22 0.008*
GMI Pallidum 0.24 0.007* 0.24 0.006*








na na 0.67 <0.001*
GMI Putamen, PmS
score, TMT part B








0.61 <0.001* 0.68 <0.001*
GMI Striatum, PmS
score
0.59 <0.001* 0.63 <0.001*
GMI Putamen, WMS
log mem
0.50 <0.001* 0.54 <0.001*
GMI Putamen, GMI
pallidum
0.42 0.001* 0.44 0.008*
Values are individual and combined contributions of the measures to
the regression model and p values
SDMT symbol digit modalities test, TMT trail making test in seconds,
WMS wechsler memory scale, PmS score psychomotor speed average
z-score, GMI glucose metabolic index, Striatum average of caudate
and putamen, T0 baseline, T1 follow up, na not applicable
* Bold value indicates significant p value\Bonferroni–Holm cor-
rected a (one-sided)
a Number correct in 90 s
b In seconds
c Number correct in 45 s






also significantly correlated with disease load (p values between 0.003 and 0.01). In addition 
striatal and pallidal metabolism showed significant negative correlations with disease load 
(p = 0.004 and p = 0.005, respectively).
At T1, comparable and in part even stronger results were found (Table 5). In addition disease 
load was now significantly correlated with the colour word card of the stroop test (p = 0.01) 
and the TMT part B (p = 0.03).
Prediction model
The measures with the highest, significant, correlations with disease load at T0 (see 
Table 5) were included, one by one, in a linear regression analysis. Age did not contribute 
significantly to the model and was therefore left out of the analyses. The largest adjusted 
R2 for the contributions of the separate measures to disease load were found for the PmS 
score (45 %) and putaminal  GMI  (44 %);  F(1, 19) = 16.32, p ≤ 0.001 and F(1, 21) = 17.73, p 
≤ 0.001, respectively (see Table 6). Most psychomotor (sub-) tests contributed significantly 
to the variance in disease load. The SDMT explained 35 % of total variance, TMT part A 26 
%, stroop colour naming card 25 % and the stroop word reading card explained 23 % of total 
variance (corrected p values between 0.002 and 0.01). The WMS subtest logical memory 
explained 22 % of the variance in disease load (p = 0.01). Of the imaging measures the 
pallidal GMI accounted for 24 % of the variance (p = 0.007) but the caudate GMI did not 
contribute significantly to disease load.
Given the small sample size the final prediction model was restricted to a maximum of three 
predictors that were entered together, in a multiple linear regression model. The best model 
for predicting disease load at baseline consisted of the putaminal GMI and the PmS score, 
together explaining 67 % of the total variance in disease load; F(2, 19) = 20.06, p < 0.001, 
described in the following regression formula: disease load = 1.94–1.61 x GMI Putamen + 
0.078 x PmS. The same regression analyses were carried out for the T1 data and resulted 
in comparable, even stronger findings. Putaminal GMI and PmS together explained 68 % of 
total variance in disease loadF(2, 21) = 22.87, p < 0.001, now yielding the following equation: 
disease load = 1.19–0.89 x GMI Putamen + 0.11 x PmS.
DISCUSSION
We studied a well-defined group of premanifest mutation carriers of HD with imaging 
and cognitive assessment at two time points, 2 years apart, in order to identify the best 
combination of clinical markers to predict the probability of HD motor onset. This motor 
onset could be determined accurately as patients were reassessed 10 years after the initial 
examination. The combination of glucose metabolism in putamen and a composite score for 
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psychomotor speed accounts for two-thirds of variance in the calculated probability of motor 
onset within 5 years. This model holds true—and thus should be considered validated—for 
measurements obtained at 2-year-follow-up. The relevance of combined clinical measures 
in predicting disease onset and disease progression had been established before8, 9, 30, as 
well has the value of FDG–PET to detect early functional brain changes in PMCs14. Our study 
is the first to show that the combination of FDG–PET and cognitive (psychomotor speed) 
measures has significant predictive value.
Our functional imaging data replicate earlier findings on metabolic alterations in premanifest 
HD. We showed that putaminal metabolism was abnormal in almost two-thirds of PMCs at 
baseline and in half of PMCs at 2-year-follow-up. This slight paradoxical decrease in the 
number of abnormal putaminal metabolism scores may be explained by the phenomenon 
of ‘regression towards the mean’. We made a rather artificial classification for individual 
imaging and cognitive performances on the basis of z-scores. Three PMCs with an abnormal 
putaminal score at baseline (z-scores slightly below-2), ‘improved’ to the low average level 
at follow-up (with z-scores slightly above-2), while their absolute putaminal scores did not 
change that much. Furthermore, the average putaminal metabolism of the PMC group 
remained stable during follow-up. We also found abnormal caudate and pallidal metabolism 
in smaller subgroups of our cohort; however, these were not significantly different from 
Co. In line with the previous evidence, this illustrates that the striatum is one of the first 
brain regions affected in HD15, 16, 31. In contrast to some other studies11, we found metabolic 
alterations to be most profound in the putamen, whereas they found the caudate nucleus 
to show the first (structural) changes in HD. We did not find a significant difference in DLPFC 
metabolism for PMCs as compared to controls. This is in contrast with Wolf et al.32, who 
found left DLPFC hypo-activation in PMCs with increasing working memory load, while 
cognition was still preserved. An explanation for this may be that different paradigms were 
used, putting another demand on DLPFC function of PMCs; i.e., during task performance 
with event-related fMRI (the Wolf study) and in resting state with static  FDG–PET (this 
study).  Yet, Wolf et al. did not find any differences in striatal activation for PMCs and controls, 
while in our cohort the striatum is clearly affected in a substantial part of PMCs. Perhaps, 
the Wolf cohort was still farther from expected motor onset than our cohort. Their PMCs 
indeed seem on average slightly younger, with slightly lower CAG repeat lengths. It could 
be that the earliest functional changes in DLPFC are best demonstrated while the brain is 
confronted with higher cognitive demands; comparison of the two imaging paradigms in a 
larger PMC cohort may elucidate the discrepancy in findings on DLPFC function in PMCs.
In our study psychomotor tasks are particularly sensitive to cognitive decline in premanifest 
HD, which is in line with the literature2, 10. In addition, our data suggest that a composite 
score of several psychomotor tasks performance may have better predictive value than 
the test scores separately. Harrington et al.33 recently suggested that two factors, ‘motor 
planning/speed’ and ‘sensory-perceptual processing’, may be  the best indicators of  time 
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to diagnosis, after controlling for disease load and motor function. However, as the authors 
mentioned, the tests they employed are experimental and lack normative data33. In contrast, 
the tests we included possess established clinical usefulness, already. It must be mentioned 
although, that some PMCs already had abnormal psychomotor speed before onset of 
overt motor symptoms, while others performed within normal range. These individual 
scores of psychomotor speed performance showed trends of meaningful correlations with 
regional striatal metabolism, which is in line with the earlier evidence from (structural) 
imaging studies34, 35. Nearly all PMCs had normal scores with respect to executive function 
and memory and this is in line with the existing evidence that alterations in information 
processing speed precede memory and executive dysfunction in PMCs8, 36. Cognitive 
performance did not change over the 2 years, in line with reports by others37, 38. Our results 
are in line with several studies that have shown a discrepancy between the progression of 
brain atrophy on structural MRI in the preclinical phase and stable, largely intact cognitive 
and clinical functioning11. This means, that in a situation of progressive neuronal cell loss, 
compensatory mechanisms must be at play to minimize functional effects of these changes. 
In addition, during increasing exposure to mutant huntingtin, neuronal dysfunction probably 
precedes neuronal cell death. In this situation it may not be surprising, that a combination 
of functional imaging (i.e., FDG–PET) and NPA appears as the most sensitive combined 
measure for predicting HD motor onset in our study.
We had the unique opportunity to evaluate the neurological status of 17 of the 22 PMCs 
10 years after baseline, thus enabling us to classify these subjects in retrospect as either far 
from or close to HD motor onset at study entry. Eight PMCs were diagnosed  with  manifest 
HD  after 10 years and none had normal putaminal glucose metabolism scores at follow-up, 
about 8 years earlier. Of the other 9 PMCs, who did not develop motor symptoms during 
the study, 4 PMCs had normal putaminal glucose metabolism scores at follow-up. Statistical 
analyses showed a trend for worse putaminal metabolism at 2-year follow-up of PMCs 
close to motor onset as compared to PMCs far from motor onset. Cognition  scores were 
comparable for both subgroups. Although one must be cautious given the small number of 
participants, a normal putaminal glucose metabolism score may imply that a PMC will not 
develop motor symptoms within 8 years.
The strengths of this biomarker study lie in the longitudinal design in which a well 
characterized cohort of PMCs was assessed using several clinical measures. Particularly 
the third neurological evaluation at 10 years after baseline provided us with important 
information about the actual closeness to motor onset of HD for most of our subjects, 
although we cannot say at what moment during follow they actually converted to HD. 
Limitations of our study are the small sample size, drop out, and incomplete data for a few 
subjects. Furthermore, radiation exposure, ligand production, and cost may limit the use of 
FDG–PET scanning. However, in recent years, FDG–PET has become more widely available, 
mainly through markedly increased demands for oncological patients. It will be important 
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to validate our results in a much larger cohort to make sure that these still hold within a 
heterogeneous population of PMCs.
In conclusion, we found a combination of functional imaging and cognitive measures to be 
of predictive value for motor onset of HD within 5 years. More specifically, the combination 
of glucose metabolism of the putamen and a composite score for psychomotor speed 
is a powerful and better predictor of motor onset of HD than each measure separately. 
The additional information about the real neurological status of most PMCs (half of them 
converted to manifest HD) 10 years after baseline, supports this conclusion. The presented 
model explained a large part of the variance in the motor onset measure at baseline, and an 
even higher amount after 2 years follow-up. Therefore, in future clinical trials a combination 
of the SDMT, TMT, stroop colour word test and putaminal glucose metabolism can be used 
to identify late-converter-PMCs.
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